Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Medicure to Announce Fiscal Year End 2018 Financial Results on April 29, 2019 | ||
By: PR Newswire Association LLC. - 25 Apr 2019 | Back to overview list |
|
WINNIPEG, April 24, 2019 /CNW/ - Medicure Inc. ("Medicure") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, will release financial results for the year ended December 31, 2018 after markets close on Monday, April 29, 2019. The financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Tuesday, April 30, 2019 at 7:30 AM Central Time (8:30 AM Eastern Time). Conference Call Info: Topic: Medicure's Fiscal Year End 2018 Results Call date: Tuesday, April 30, 2019 Time: 7:30 AM Central Time (8:30 AM Eastern Time) Canada toll-free: 1 (888) 465-5079 Canada toll: 1 (416) 216-4169 United States toll-free: 1 (888) 545-0687 Passcode: 8925377# Webcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: https://www.medicure.com/investors You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website. About Medicure Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS™ device in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com. To be added to Medicure's e-mail list, please visit: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. View original content:http://www.prnewswire.com/news-releases/medicure-to-announce-fiscal-year-end-2018-financial-results-on-april-29-2019-300837919.html SOURCE Medicure Inc. |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |